New data show that at a high dose, the CAR-T therapy developed by Bluebird and Celgene shrank tumor in 95 percent of patients and made cancer undetectable in 50 percent. The cancer still returned for most patients.
More From BioPortfolio on "Bluebird Bio's "Impressive" Killer Cells Battle Myeloma, But Are Not A Cure"